Marker Therapeutics Inc (MRKR)

[pharmeng]

There's still a lot unknown regarding versus different PD-1/PD-L1 mAbs, just b/c it didn't work in Lung does not mean it will not work in others.

For example, Durva worked in bladder, but Genentech's PD-L1 drug failed recently.

Opdivo (BMS) worked in H&N, but Keytruda (Merck) just reported a failure.

Keytruda worked in NSCLC first line, but Opdivo failed.

He could not realistically give any guidance on this situation.